Endothelix to Showcase the First FDA-Cleared, Fully Automated Office-Based Vascular Function Test at AMMG 2014
VENDYS aims to assist physicians in the early detection and treatment of cardiovascular disease, the number one cause of death in the United States.
Houston, Texas (PRWEB) April 13, 2014
As hundreds of physicians whose practices focus on wellness and age management medicine gather in Orlando, FL to attend their annual conference (AMMG), Endothelix is using the forum to showcase VENDYS, the first FDA-cleared, fully automated, operator-independent, office-based vascular function measurement device. VENDYS aims to assist physicians in the early detection and treatment of cardiovascular disease, the number one cause of death in the United States.
Developed by Houstons innovative cardiologist and researcher, Dr. Morteza Naghavi, the VENDYS technology was awarded $ 1M by the Texas Governors Office as a Texas emerging medical technology. VENDYS was featured by Vasomedical Inc. at the 2014 American College of Cardiology conference last month and later this month (April 24-27, 2014), it will be presented at the 16th Clinical Applications for Age Management Medicine (AMMG) conference, to be held at the JW Marriott/Ritz Carlton, Grande Lakes, Orlando, Florida.
The VENDYS automated technology is designed to help physicians detect impaired vascular reactivity and endothelial dysfunction. In short, it measures the fitness of a patients vascular system. It is the only FDA-cleared fully automated office-based test which provides a patient-friendly report in 15 minutes. The test uses a standard arm-cuff based reactive hyperemia procedure, but instead of using an expensive ultrasound Doppler system for measuring blood flow and thus requiring an experienced ultrasonographer, VENDYS uses smart temperature sensors and algorithms to measure blood flow. Because blood is warm, the more blood flow the higher the temperature at the fingertip. The VENDYS test begins with an automated blood pressure measurement, followed by a tightening of the arm-cuff on the right arm. During the cuff occlusion period, fingertip temperature in the right hand falls due to the absence of warm circulating blood. Once the cuff is released, blood flow rushes into the forearm and hand, causing a temperature rebound in the fingertip which is directly proportional to the vascular reactivity. The higher the temperature rebound, the better the vascular function.
For more information, contact Endothelix at info(at)endothelix(dot)com.
Endothelix, Inc. is a cardiovascular device company based in Houston, Texas and is focused on non-invasive cardiovascular diagnostic technologies. The company originated from the Texas Medical Center-Houston from a collaborative project between the Texas Heart Institute and The University of Texas Health Science Center at Houston. Endothelix received a $ 1 million award from the Texas Emerging Technology Fund to develop the VENDYS technology.
Endothelixs first product is VENDYS, a non-invasive, inexpensive, and easy-to-use vascular function test. VENDYS is the only FDA-cleared, fully automated, operator-independent, office-based vascular function device in the market. For more info, visit http://www.endothelix.com.
It is the goal of the Age Management Medicine Group (AMMG) to provide education and information on the specialty of Age Management Medicine to physicians and healthcare professionals through evidence-based continuing medical education conferences, workshops, seminars, publications and web media. The Group membership consists of leading healthcare professionals, physicians, practitioners, researchers, medical associations and providers of products and services. Age Management Medicine is a proactive, preventative approach focused on preservation of optimum human function and quality of life making every effort to modulate the process of aging prior to the onset of degenerative aging. The basic tenets of Age Management Medicine are patient evaluation through extensive medical history, lifestyle assessment, physical examination and laboratory evaluation to establish personalized proactive treatment plans consisting of proper diet, exercise, stress management and appropriate medical interventions. For more info, visit http://www.agemed.org.
Random Contribution Link in reference to Norgesspill –
8 Responses to 'Endothelix to Showcase the First FDA-Cleared, Fully Automated Office-Based Vascular Function Test at AMMG 2014'
Leave a Reply
You must be logged in to post a comment.